You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Diagnostic performance of five non-invasive tests for determining significant steatosis (> 33% of hepatocytes)

From: Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C

Significant steatosis (> 33% of hepatocytes)
Test APRI M-APRI FIB-4 M-FIB-4 B-AST
AUROC (95% CI) 0.837 (0.657–0.945) 0.923 (0.820–0.999) 0.683 (0.488–0.840) 0.942 (0.792–0.994) 0.942 (0.792–0.994)
Cut-off 0.656 0.577 0.216 0.179 92.82
Sensitivity (95% CI) 75 (19.4–99.4) 100 (39.8–100) 75 (19.4–99.4) 100 (39.8–100) 100 (39.8–100)
Specificity (95% CI) 88.46 (69.8–97.6) 92.3 (74.9–99.1) 73.1 (52.2–88.4) 88.46 (69.8–97.6) 92.3 (74.9–99.1)
+ PV 50.0 (23.1–76.9) 66.7 (34.6–88.3) 30.0 (15.5–50.0) 57.1 (31.5–79.4) 66.7 (34.6–88.3)
- PV 95.8 (80.7–99.2) 100 95.0 (77.4–99.1) 100 100
  1. APRI aspartate-to-platelet ratio index, FIB-4 Fibrosis-4 index, M-APRI modified aspartate-to-platelet ratio index (BMI z-score x APRI), M-FIB-4 modified Fibrosis-4 index (BMI z-score x FIB-4), B-AST BMI z-score x AST, AUROC area under the receiver operating characteristic, 95% CI 95% confidence interval, + PV positive predictive value, − PV negative predictive value